RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…
Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Alderley Park, Cheshire U.K. Infex Therapeutics, a leading anti-infectives…
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
First subject dosed in Phase I study to evaluate safety and tolerability of…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022…